RecruitingMetastatic Cancer
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
Eligible age
18+ yrs
Accepts
All genders
Locations
2 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
A randomized research study of drugs nivolumab and pembrolizumab in patients with locally advanced or metastatic cancers. Based on data from earlier studies it appears that the drugs can be given less often then the currently approved schedule. This trial will compare drug levels from the blood from standard interval dosing levels versus taking the drugs less often.
Sponsor: University of Chicago
You may qualify if…
- ✓ Patients with locally advandced or metastatic cancer whose physician has determined they are candidates for treatment with nivolumab or pembrolizumab
- ✓ 18 years old or older
- ✓ Measurable disease per RECIST criteria
You may not qualify if…
- ✕ Patients who have previously received immune checkpoint inhibitors or investigational monoclonal antibody therapy.
- ✕ Patients whose treatment plan is to receive ipilimumab or other anti-CTLA4 monoclonal antibody in combination with either nivolumab or pembrolizumab.
- ✕ Ipilimumab and nivolumab combination are not eligible for this trial.
- ✕ (Note: Patients whose planned treatment is the combination of anti-PD-1 and tyrosine kinase inhibitor such as pembrolizumab-axitinib or the combination of traditional cytotoxic chemotherapy and anti-PD-1 are eligible)
Where it's recruiting
Source: ClinicalTrials.gov · NCT04295863 · last updated 2025-10-01